Long-Term Colestyramine Treatment Prevents Cholestatic Attacks in Refractory Benign Recurrent Intrahepatic Cholestasis Type 1 Disease

Hepatology. 2021 Jul;74(1):522-524. doi: 10.1002/hep.31671. Epub 2021 Jun 28.

Authors

Eleni Koukoulioti^#¹, Athanasia Ziagaki¹, Susanne N Weber², Frank Lammert², Thomas Berg¹

Affiliations

¹ Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.
² Department of Medicine II, Saarland University Medical Center, Homburg, Germany.

^# Contributed equally.

PMID: 33277690
DOI: 10.1002/hep.31671

No abstract available

Publication types

Case Reports

MeSH terms

Administration, Oral
Cholestasis, Intrahepatic / drug therapy*
Cholestyramine Resin / administration & dosage*
Drug Resistance
Humans
Male
Middle Aged
Patient Acuity
Recurrence
Secondary Prevention / methods*
Treatment Outcome

Substances

Cholestyramine Resin

Supplementary concepts

Cholestasis, progressive familial intrahepatic 1